
First allogeneic cancer immunotherapy hits market
On December 20th, the European Commission approved Tabelecleucel (EbvalloTM) as a monotherapy for the treatment of adult and paediatric patients who...

Neurodegenerative disorders are being fought with €28m
The Danish biotech Teitur Trophics ApS, aiming to treat chronic neurological disorders, has completed a €28m Series A funding. With the money, Teitur...

Confo Therapeutics and Lilly partner to advance CFTX-1554
Under the agreement, Confo Therapeutics BV got a $40m upfront and milestone payments totalling $590m for licencing its clinical stage angiotensin II...

Ethris inks €15m deal with Indian Ciplas
The investment is aimed at establishing a long-term strategic partnership until the end of Q1/2023 between Cipla and Ethris for the development of...

AMsilk scaling up through Evonik collaboration
Just one week after AMSilk inked a collaboration agreement on protein engineering of its silk protein to target new applications with Brain Biotech...

Evidence of deliberate climate damage
For decades, some members of the fossil fuel industry tried to convince the public that a causative link between fossil fuel use and climate warming...

First hints for leukopenia diagnostic in MS
Disease-modifying therapies for multiple sclerosis (MS) may positively influence the composition of the intestinal flora. At least this is what a...